Chapter Member Anniversaries: March 2021

Posted by ISPE Boston
On March 4, 2021

Please congratulate the following members celebrating milestone anniversaries in March 2021. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Saboo Aghababayan, MS, MBA, Genzyme Stig Bockman-Pedersen, CCQV Services Matthew J. Camelio, Thermo Fisher Ronald C. Case, RCC Associates Dr. Charles L. Cooney, PhD, MIT Chemical Engineering […]

Welcome New Members February 2021!

Posted by ISPE Boston
On March 4, 2021

We would like to introduce the Members who joined ISPE in February 2021, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

Pandion Therapeutics to be Acquired by Merck

Posted by ISPE Boston
On March 3, 2021

Merck and Watertown-based Pandion Therapeutics, a clinical-stage biotech developing novel therapeutics targeting autoimmune diseases, have agreed that Merck will acquire Pandion for $60 per share or approximately $1.85 billion. The transaction is expected to close in the first half of 2021. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. […]

Beam Therapeutics Buys Drug Delivery Biotech

Posted by ISPE Boston
On March 3, 2021

Gene-editing biotech Beam Therapeutics has acquired Guide Therapeutics, a developer of nonviral drug delivery vehicles for genetic medicines, further expanding the potential reach of Beam’s genetic medicines into new target tissues and diseases. “Since our founding, Beam’s strategy has been to establish the leading, fully integrated platform for precision genetic medicine,” said Beam CEO John […]

Ensoma Launches, Enters Collaboration with Takeda

Posted by ISPE Boston
On March 3, 2021

Boston-based Ensoma, formally launched in early February, has entered into a strategic collaboration with Takeda. The agreement grants Takeda an exclusive worldwide license to Ensoma’s Engenious™ vectors for up to five rare disease indications. Takeda will make an equity investment of $10 million in Ensoma’s Series A Preferred Stock with the potential for $100 million […]

Get Involved! Volunteer with ISPE Today

Posted by ISPE Boston
On February 22, 2021

Had enough of social isolation? Bored with talking to your cat instead of colleagues? Are you feeling like you need to change out of sweatpants? We can’t promise that you will never attend a Zoom meeting, but we can promise that you will connect with some of the nicest folks in the biopharma industry and […]

Biotech Newcomer to Purchase Sanofi Plant in Allston

Posted by ISPE Boston
On February 19, 2021

National Resilience, a biotech newcomer launched in November 2020 and headquartered in Boston and San Diego, is poised to purchase the Sanofi bio-manufacturing plant in Allston. According to its website, Resilience “will actively invest in developing powerful new technologies to manufacture complex medicines that are defining the future of therapeutics, including cell and gene therapies, […]

Curevac and GSK to Co-Develop Next Gen mRNA COVID Vaccine

Posted by ISPE Boston
On February 19, 2021

Curevac and GlaxoSmithKline will partner to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. GSK will also support the manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021. Through this new exclusive […]

Selecting Your Off-site GMP BioPharma Storage Provider

Posted by Michael Davanzo
On February 19, 2021

Abstract Off-site storage of GMP biological and pharmaceutical products and medical devices is a critical resource for biopharmaceutical companies, contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs) facing storage and overflow issues. There are many critical factors to consider when selecting an off-site GMP storage provider. Among the most crucial factors to […]

CONTINUUS Pharmaceuticals Wins Government Contract to Manufacture Critical Meds

Posted by ISPE Boston
On February 11, 2021

Woburn-based CONTINUUS Pharmaceuticals has won a $69.3 million U.S. government contract to facilitate domestic production of three medicines used to treat critically ill patients, including those with COVID-19. “…In addition to streamlining continuous, environmentally friendly, and cost-efficient production of these medicines, this contract will help us build a state-of-the-art facility that will address urgent pharmaceutical supply chain […]

Page 51 of 117«‹49 505152 53 ›»